Polymyxin Combination Therapy and the Use of Serum Bactericidal Titers in the Management of KPC-Producing Klebsiella pneumoniae Infections: A Report of 3 Cases.
作者信息
Gomez Eric, Sanchez Martha, Gul Zonaira, Urban Carl, Mariano Noriel, Eng Robert H K, Huang David B, Chiang Tom
机构信息
Infectious Disease Division, Department of Medicine, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ 07103-2714, USA.
出版信息
Case Rep Med. 2011;2011:659769. doi: 10.1155/2011/659769. Epub 2011 Nov 28.
Abstract
Management of patients with KPC-harboring Enterobacteriaceae has become a significant and challenging scenario. We report three cases of KPC-producing Klebsiella pneumoniae bacteremia that were successfully treated using combination therapy with polymyxin B and other antimicrobials. Serum bactericidal titers were determined and provided additional clinical guidance in the management of such patients.
摘要
相似文献
1
Polymyxin Combination Therapy and the Use of Serum Bactericidal Titers in the Management of KPC-Producing Klebsiella pneumoniae Infections: A Report of 3 Cases.
Case Rep Med. 2011;2011:659769. doi: 10.1155/2011/659769. Epub 2011 Nov 28.
2
Assessment of Combined Polymyxin B and Minocycline Therapy against Klebsiella pneumoniae Carbapenemase (KPC)-Producing K. pneumoniae.
Antimicrob Agents Chemother. 2017 Jun 27;61(7). doi: 10.1128/AAC.00073-17. Print 2017 Jul.
3
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
4
Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens.
Antimicrob Agents Chemother. 2012 Apr;56(4):2108-13. doi: 10.1128/AAC.06268-11. Epub 2012 Jan 17.
5
Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.02121-16. Print 2017 Feb.
6
Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports.
Ann Clin Microbiol Antimicrob. 2012 Dec 13;11:32. doi: 10.1186/1476-0711-11-32.
7
Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection.
Int J Antimicrob Agents. 2019 Feb;53(2):152-157. doi: 10.1016/j.ijantimicag.2018.10.010. Epub 2018 Oct 26.
8
Comparative serum bactericidal activity of meropenem-based combination regimens against extended-spectrum beta-lactamase and KPC-producing Klebsiella pneumoniae.
Eur J Clin Microbiol Infect Dis. 2019 Oct;38(10):1925-1931. doi: 10.1007/s10096-019-03628-6. Epub 2019 Jul 6.
9
Polymyxin B and fosfomycin thwart KPC-producing Klebsiella pneumoniae in the hollow-fibre infection model.
Int J Antimicrob Agents. 2018 Jul;52(1):114-118. doi: 10.1016/j.ijantimicag.2018.02.010. Epub 2018 Feb 24.
10
Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
Int J Antimicrob Agents. 2011 Mar;37(3):244-7. doi: 10.1016/j.ijantimicag.2010.10.031. Epub 2011 Jan 13.
引用本文的文献
1
Polymyxin-B Combination Therapy - A Dire Need to Safeguard Our Last Hope.
J Glob Infect Dis. 2016 Jul-Sep;8(3):125-6. doi: 10.4103/0974-777X.188599.
本文引用的文献
1
Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
Int J Antimicrob Agents. 2011 Mar;37(3):244-7. doi: 10.1016/j.ijantimicag.2010.10.031. Epub 2011 Jan 13.
2
Successful treatment of pan-resistant Klebsiella pneumoniae pneumonia and bacteraemia with a combination of high-dose tigecycline and colistin.
J Med Microbiol. 2010 Nov;59(Pt 11):1383-1386. doi: 10.1099/jmm.0.023010-0. Epub 2010 Aug 5.
3
In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae.
J Clin Microbiol. 2010 Oct;48(10):3558-62. doi: 10.1128/JCM.01106-10. Epub 2010 Aug 4.
4
In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase- producing Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2010 Oct;54(10):4112-5. doi: 10.1128/AAC.00026-10. Epub 2010 Jul 26.
5
Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection.
J Antimicrob Chemother. 2010 Jun;65(6):1119-25. doi: 10.1093/jac/dkq108. Epub 2010 Apr 8.
6
In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli.
Antimicrob Agents Chemother. 2010 Jun;54(6):2732-4. doi: 10.1128/AAC.01768-09. Epub 2010 Apr 5.
7
In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin.
Antimicrob Agents Chemother. 2010 Jan;54(1):526-9. doi: 10.1128/AAC.01235-09. Epub 2009 Nov 9.
8
Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection.
J Clin Microbiol. 2009 May;47(5):1611-2. doi: 10.1128/JCM.02466-08. Epub 2009 Mar 4.
9
Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies.
Clin Microbiol Infect. 2008 Sep;14(9):816-27. doi: 10.1111/j.1469-0691.2008.02061.x.
10
Polymyxins revisited.
Clin Microbiol Rev. 2008 Jul;21(3):449-65. doi: 10.1128/CMR.00006-08.
Zotero 插件